Abbott Laboratories (Abbott Laboratories) Change In Working Capital

: $-2,475 Mil (TTM As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

Abbott Laboratories's change in working capital for the quarter that ended in Dec. 2023 was $-1,524 Mil.

Abbott Laboratories's change in working capital for the fiscal year that ended in Dec. 2023 was $-2,475 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Abbott Laboratories Change In Working Capital Historical Data

The historical data trend for Abbott Laboratories's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

-1,331.00

-892.00

-771.00

-1,519.00

-2,475.00

Abbott Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital																114.00	-186.00	-444.00	-321.00	-1,524.00

Abbott Laboratories Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,475 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Abbott Laboratories Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories (Abbott Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

ABT:Mexico 0Q15:UK ABL:Germany ABL:Germany ABL:Germany ABL:Germany ABT:Chile ABT:Switzerland ABTT34:Brazil ABT:Austria ABT:Argentina

Address

100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400

Website

https://www.abbottinvestor.com

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Executives

Andrea F Wainer	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr.	officer: VICE PRESIDENT	C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman	director	3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone	officer: EXECUTIVE VICE PRESIDENT	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau	officer: Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady	director	50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift	officer: Senior Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive	officer: Senior Vice President	100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland	officer: Executive Vice President	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt	officer: Executive Vice President	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck	officer: Vice President, Controller	100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092